Nonalcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease
worldwide and a leading indication for liver transplantation in the United States. NAFLD …

Abstract Male hypogonadism affects 10–30% of the male population and is often under-
recognized and under-treated. Different replacement formulations exist, each with specific …

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in people with
diabetes with no available treatment. AIM To explore the effect of testosterone treatment on …

Background Male hypogonadism (testosterone level< 300 ng/dl) is a clinical syndrome that
results from failure of the testis to produce physiological levels of testosterone. Most …

Background and aims Metabolic dysfunction-associated fatty liver disease (MAFLD) has
emerged as a valuable marker for identifying individuals at increased risk of metabolic …

Background Testosterone deficiency results from insufficient testosterone production.
Testosterone therapy may require dose titration to reach eugonadal serum testosterone …

Background/aims Low serum testosterone is common in cirrhotic men, but the impact of
disease aetiology remains uncertain. This study compares serum total testosterone (TT) …

Obesity-related gonadal dysfunction in males has been defined recently as male obesity
secondary hypogonadism (MOSH). Affected individuals present with signs and symptoms …

Introduction Testosterone deficiency is a clinical disorder due to either failure of the testes to
produce testosterone or failure of the hypothalamus or pituitary to produce sufficient …

Nonalcoholic fatty liver disease (NAFLD), recently proposed to be renamed to metabolic
dysfunction-associated steatotic liver disease (MASLD), is a major global public health …